Table 2.
Univariate Analysis of Mortality in Patients With COVID-19 Breakthrough Infection
| Variable | Alive | Died From COVID-19a | P | |
|---|---|---|---|---|
| n = 951 | n = 19 | |||
| Age, y | Mean ± SD | 57.6 ± 18.2 | 76.1 ± 11.1 | <.001 |
| Male sex | No. (%) | 409 (42) | 8 (42) | .974 |
| Health care worker | No. (%) | 254 (26) | 1 (5) | .035 |
| Body mass index | No. (%) | .365 | ||
| 30–39 kg/m2 | 254 (32) | 7 (37) | ||
| ≥40 kg/m2 | 72 (9) | 4 (21) | ||
| Smoking history | 372 (39) | 11 (58) | .100 | |
| Chronic kidney disease | No. (%) | 65 (7) | 4 (21) | .039 |
| COPD | No. (%) | 105 (11) | 7 (37) | .003 |
| Cardiovascular disease | No. (%) | 132 (14) | 10 (53) | .002 |
| Immunocompromised | 218 (23) | 7 (37) | .167 | |
| Solid organ transplant | 31 (3) | 2 (11) | .131 | |
| Hematologic malignancy | No. (%) | 21 (2) | 2 (11) | .070 |
| Vaccine type | No. (%) | .059 | ||
| JNJ78436735 | 55 (6) | 2 (11) | ||
| mRNA1273 | 181 (19) | 7 (37) | ||
| BNT162b2 | 727 (75) | 10 (53) | ||
| Time to diagnosis, d | Mean ± SD | 135 ± 61 | 155 ± 30 | .011 |
Mean is presented with standard deviation. Significant P values are bolded.
Abbreviations: BNT162b2, Pfizer vaccine; COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease 2019; ICU, intensive care unit; JNJ78436735, Janssen vaccine; LOS, length of stay; mRNA1273, Moderna vaccine.
Twelve patients were excluded due to death from non-COVID-19-related events.